Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci 192Ir source, and neoadjuvant hormonal manipulation for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 1, 2006, Pages 38-47

  Izard, Michael A ^a   Haddad, Richard L ^a   Fogarty, Gerald B ^a   Rinks, Adrian ^a   Dobbins, Timothy ^a   Katelaris, Philip ^a  

^a Mater Hospital   (Australia)

Author keywords

brachytherapy; external beam radiotherapy; Iridium 192; PDR; Prostate cancer

Indexed keywords

ANTIGENS; DISEASES; HORMONES; IRIDIUM; ONCOLOGY; PATIENT MONITORING; TOXICITY; TUMORS;

BRACHYTHERAPY; EXTERNAL BEAM RADIOTHERAPY; IRIDIUM-192; PDR; PROSTATE CANCER;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN AGONIST; IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER SURVIVAL; CYSTITIS; DISEASE SEVERITY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; URETHRA STRICTURE; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROCTITIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; UROGENITAL SYSTEM;

EID: 33746821869     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.04.002     Document Type: Article

References (29)

1. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
2. Vicini F., Vargas C., Gustafson G., et al. High dose rate brachytherapy in the treatment of prostate cancer. World J Urol 21 (2003) 220-228
3. Deger S., Boehmer D., Turk I., et al. High dose rate brachytherapy of localised prostate cancer. European Urology 41 (2002) 420-426
4. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer. California Endocurietherapy's 10 year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
5. Hermanek P., and Sobin L.H. UICC TNM Classification of malignant tumours. 4th ed. (1992), Springer-Verlag, Berlin
6. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
7. Syed A.M.N., Puthawala A., Sharma A., et al. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer control 8 (2001) 511-521
8. Mate T.P., Gottesman J.E., Hatton J., et al. High-dose-rate after-loading 192Iridium prostate brachytherapy. Feasibility report. Int J Radiat Oncol Biol Phys 41 (1998) 525-533
9. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169 (2003) 974-980
10. Pellizon A., Nadalin W., Salvajoli J., et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 66 (2003) 167-172
11. Stevens M.J., Stricker P.D., Saalfeld J., et al. Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation. Initial Australian experience. Australasian Radiology 47 (2003) 152-160
12. Demanes D.J., Rodriguez R.R., and Altieri G.S. High dose rate prostate brachytherapy. The California Endocurietherapy (CET) Method. Radiother Oncol 57 (2000) 289-296
13. Smathers S., Wallner K.E., Sprouse J., et al. Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 1207-1211
14. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
15. Kuban D.A., Thames H.D., and Levy L.B. Radiation for prostate cancer. Use of biochemical failure as an endpoint following radiotherapy. World J Urol 21 (2003) 253-264
16. Lawton C.A., Won M., Pilepich M.J., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate. Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 (1991) 935-939
17. Thames T., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
18. Kuyu H., Lee W.R., Bare R., et al. Recent advances in the treatment of prostate cancer. Ann Oncol 10 (1999) 891-898
19. Langley S.E.M., and Laing R. Prostate brachytherapy has come of age. A review of the techniques and results. BJU International 89 (2002) 241-249
20. Kneebone A., Turner S., Berry M., et al. Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Australas Radiol 47 (2003) 422-427
21. Dale R.G., and Jones B. The clinical radiobiology of brachytherapy. B J Radiol 71 (1998) 465-483
22. Zeman E.M. Scientific foundations of radiation oncology. In: Gunderson L., and Tepper J. (Eds). Clinical radiation oncology. 1st ed. (2000), Churchill Livingstone, New York
23. Nag S., Ellis R.J., Merrick G.S., et al. American brachytherapy society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 462-470
24. Galalae R.M., Kovacs G., Schultze J., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 81-90
25. Eulae S.M., Van Hollebeke L., Cavanagh W., et al. High dose rate iridium 192 brachytherapy in localised prostate cancer. Results and toxicity with maximum follow-up of 10 years. [Abstract]. Int J Radiat Oncol Biol Phys 48 Suppl. (2000) 149
26. Galalae R.M., Martinez A.A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
27. Jani A.B., Basu A., Abdalla I., et al. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. Am J Clin Oncol 26 (2003) 382-385
28. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
29. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150 (1993) 110-114